Key Takeaways Prothena posted a Q3 loss of $0.67 per share on$2.4M revenues, missing the consensus mark.R&D costs fell 43% year over year, while cash holdings stood attotaled $331.7M with no debt.Pipeline advances include Roche's PARAISO Parkinson's trial and FDA Fast Track for Alzheimer's drugs.Prothena Corporation (PRTA) reported third-quarter 2025 adjusted loss per share (excluding restructuring costs) of 67 cents, much wider than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quart ...